Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

QUASAR Collaborative Group

doi:10.1016/S0140-6736(00)02214-5

Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

QUASAR Collaborative Group

Research output: Contribution to journal › Article › peer-review

248 Citations (Scopus)

Abstract

Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

Original language	English
Pages (from-to)	1588-96
Number of pages	9
Journal	Lancet
Volume	355
Issue number	9215
DOIs	https://doi.org/10.1016/S0140-6736(00)02214-5
Publication status	Published - 6 May 2000

Keywords

Adjuvants, Immunologic
Antimetabolites, Antineoplastic
Chemotherapy, Adjuvant
Colonic Neoplasms
Drug Therapy, Combination
Fluorouracil
Humans
Leucovorin
Levamisole
Neoplasm Recurrence, Local
Radiotherapy, Adjuvant
Rectal Neoplasms
Survival Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(00)02214-5

Cite this

@article{1f71c1f0e11441ebb6914a8bbd3f2776,

title = "Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.",

abstract = "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.",

keywords = "Adjuvants, Immunologic, Antimetabolites, Antineoplastic, Chemotherapy, Adjuvant, Colonic Neoplasms, Drug Therapy, Combination, Fluorouracil, Humans, Leucovorin, Levamisole, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Rectal Neoplasms, Survival Analysis",

author = "Steele, \{Robert J. C.\} and \{QUASAR Collaborative Group\}",

year = "2000",

month = may,

day = "6",

doi = "10.1016/S0140-6736(00)02214-5",

language = "English",

volume = "355",

pages = "1588--96",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9215",

}

TY - JOUR

T1 - Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer

T2 - a randomised trial.

AU - QUASAR Collaborative Group

A2 - Steele, Robert J. C.

PY - 2000/5/6

Y1 - 2000/5/6

N2 - Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

AB - Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved survival.

KW - Adjuvants, Immunologic

KW - Antimetabolites, Antineoplastic

KW - Chemotherapy, Adjuvant

KW - Colonic Neoplasms

KW - Drug Therapy, Combination

KW - Fluorouracil

KW - Humans

KW - Leucovorin

KW - Levamisole

KW - Neoplasm Recurrence, Local

KW - Radiotherapy, Adjuvant

KW - Rectal Neoplasms

KW - Survival Analysis

U2 - 10.1016/S0140-6736(00)02214-5

DO - 10.1016/S0140-6736(00)02214-5

M3 - Article

C2 - 10821362

SN - 0140-6736

VL - 355

SP - 1588

EP - 1596

JO - Lancet

JF - Lancet

IS - 9215

ER -

Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this